文献速递炎症性肠病

肿瘤坏死因子拮抗剂在老年溃疡性结肠炎患者中的安全性与疗效:随机试验患者水平汇总分析

Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-05-01

该研究基于4项随机试验的个体患者数据,比较60岁及以上与60岁以下溃疡性结肠炎患者接受抗TNF治疗的安全性与疗效。老年患者严重不良事件和住院比例更高,但抗TNF治疗相关风险在老年与年轻患者间无显著差异;诱导和维持缓解的疗效在两组间亦无显著差异。

要点

  • 老年UC患者抗TNF治疗前严重不良事件和住院基线风险更高。
  • 抗TNF治疗未显著增加老年患者严重不良事件、住院或严重感染风险。
  • 抗TNF诱导和维持缓解疗效在老年与年轻患者间无显著差异。

核心结论

  • 老年UC患者严重不良事件基线风险较高,但抗TNF治疗未在老年与年轻患者间带来额外风险差异。
  • 抗TNF治疗在老年与年轻患者中的诱导和维持缓解疗效无显著差异。

研究设计与样本

  • 基于4项抗TNF治疗UC随机试验的个体患者水平数据汇总分析,共纳入2257例患者,其中231例为60岁及以上。
  • 采用随机效应逻辑回归模型,按年龄评估抗TNF治疗的安全性和疗效,并校正混杂因素和试验水平效应。

主要发现

  • 老年患者接受抗TNF治疗时严重不良事件发生率为20%,住院率为14.4%;年轻患者分别为10.2%和5.2%。
  • 与安慰剂相比,抗TNF治疗在老年患者中严重不良事件减少5.4%,住院减少6.7%,严重感染减少3.1%;年轻患者对应变化为减少2.4%、减少2.5%和增加0.7%。
  • 老年与年轻患者抗TNF诱导缓解的比值比为1.05(95%CI 0.33-3.39),维持缓解的比值比为0.49(95%CI 0.18-1.33),均无显著差异。

关键数值与推荐

  • 严重不良事件定义为死亡、危及生命事件、住院和/或显著残疾。
  • 临床缓解由试验研究者定义为诱导或维持治疗结束时Mayo评分≤2且无子评分>1。

临床怎么用

  • 对老年UC患者启动抗TNF治疗前应充分评估严重不良事件和住院的基线风险。
  • 抗TNF治疗在老年UC患者中未显示额外安全风险,疗效与年轻患者相当,可作为治疗选择。

局限性

  • 为随机试验数据的汇总分析,可能存在选择偏倚和未测量混杂因素。
  • 老年患者样本量相对较小(231例),可能影响亚组分析的精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment of older patients (more than 60 years) with ulcerative colitis (UC) can be a challenge, because they might be more vulnerable to adverse events (AEs). We determined the effects of age on the safety and efficacy of anti-tumor necrosis factor (TNF) therapy in a pooled analysis of data from randomized trials. METHODS: We obtained individual patient-level data from 4 trials of anti-TNF therapy for patients with UC from the Yale Open Data Access Project. Participants were assigned to groups of older age (60 years or older) and younger age (younger than 60 years). The primary outcome was difference in serious AEs (SAEs), defined as death, life-threatening event, hospitalization, and/or significant disability. Secondary outcomes were severe infections, non-severe infections, neoplasms, and achievement of clinical remission, defined by trial investigators as Mayo score ≤ 2 with no sub-score >1 at the end of induction or maintenance therapy. A random effects logistic regression model was fitted to estimate the effect of anti-TNF therapy on safety and efficacy by age, adjusting for confounders and trial-level effects. RESULTS: The study cohort included 2257 patients (231 60 years or older). Higher proportions of older patients receiving anti-TNF therapy had SAEs (20%) and hospitalizations (14.4%), compared with younger patients (10.2% had SAEs and 5.2% were hospitalized); there were no significant differences between groups in proportions with severe or non-severe infections. Compared with placebo, there was no significant difference in safety risks associated with anti-TNF therapy (SAEs reduced by 5.4% in older patients vs reduction of 2.4% in younger patients; hospitalizations reduced by 6.7% in older patients vs reduction of 2.5% in younger patients; severe infections reduced by 3.1% vs increase of 0.7% in younger patients). There was no significant difference in between older vs younger patients in efficacy of anti-TNF therapy in inducing remission (odds risk ratio, 1.05, 95% CI, 0.33-3.39) or in maintaining remission (odds risk ratio, 0.49; 95% CI, 0.18-1.33). CONCLUSIONS: In a pooled analysis of data from randomized trials, we found that older patients with UC have an increased baseline increased risk of SAEs, but no increase in risk can be attributed to anti-TNF therapy in older vs younger patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Cheng D, Cushing KC, Cai T, et al. Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials. Clin Gastroenterol Hepatol. 2020. PMID: 32371165. doi:10.1016/j.cgh.2020.04.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。